by Hemophilia treatment involves replacing or supplementing clotting factors that are missing or deficient in people with hemophilia. The major types of hemophilia are hemophilia A, which is a deficiency of clotting factor VIII and hemophilia B, which is a deficiency of clotting factor IX. The treatment options include on-demand treatment, prophylaxis, and immune tolerance induction therapy. The growing availability of extended half-life recombinant coagulation factors and gene therapy creates new opportunities in hemophilia treatment.
The Global U.S. Hemophilia Treatment Market Size is estimated to be valued at US$ 4.21 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the U.S. Hemophilia Treatment are Takeda Pharmaceutical Company Limited, Sanofi, Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc. among others. These key players are focused on entering into partnerships and conducting clinical trials to expand their product portfolio. Moreover, the availability of biosimilars and development of novel treatment therapies such as gene therapy are expected to provide significant growth opportunities in the market over the forecast period. In addition, growing awareness about hemophilia treatment and support from various government and non-government organizations are contributing to the expansion of the U.S hemophilia treatment market globally over the next few years.
Market Drivers
The rising incidence and prevalence of hemophilia A and B disorders mainly drives the growth of the U.S. hemophilia treatment market. As per Centers for Disease Control and Prevention data, around 1 in 5,000 births have hemophilia and annually 400 babies are born with the disorder in the U.S. Moreover, the increase in economic burden associated with hemophilia treatment as it requires lifelong care is also expected to fuel the demand for effective and low-cost therapies in coming years. In addition, the rising healthcare expenditure in the U.S. for advanced hemophilia therapies such as gene therapy and strong pipeline of emerging therapies are projected to boost the market growth significantly over the forecast period.
Pest Analysis
Political: Hemophilia treatment products face stringent regulations for approval in the U.S. However, favorable government policies support growth of this sector through reimbursement programs.
Economic: Rising disposable income and healthcare spending in the U.S. drive demand for advanced hemophilia drugs. The high cost of treatment remains a challenge for widespread adoption.
Social: Growing awareness about hemophilia and availability of effective treatment options encourage patients to seek medicare. Non-profit organizations help patients access therapies.
Technological: Biotechnology and gene therapy innovations promise new treatment avenues with increased efficacy and reduced dosing frequency. Data-driven precision approaches could enhance individual care.
The U.S. Midwest and West regions currently account for over 60% of the hemophilia treatment market value due to high concentration of key market players and healthcare facilities.
The South region is poised to emerge as the fastest expanding market during the forecast period. This growth can be attributed to rising hemophilia prevalence, increasing access to insurance, and establishment of specialized treatment centers in populous states such as Texas and Florida.
What Are The Key Data Covered In This U.S. Hemophilia Treatment Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the U.S. Hemophilia Treatment Market’s growth between 2024 and 2031.
:- Accurate calculation of the size of the U.S. Hemophilia Treatment Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- U.S. Hemophilia Treatment Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of U.S. Hemophilia Treatment Market vendors
FAQ’S
Q.1 What are the main factors influencing the U.S. Hemophilia Treatment market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top U.S. Hemophilia Treatment Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the U.S. Hemophilia Treatment market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
